Popular Trials
Nutraceutical Supplement
Nutraceutical Supplements for Alopecia
"This trial is a study at one location where they are testing hair supplements that are already on the market to see if they can help with thinning hair by addressing the main reasons for hair loss."
Popular Filters
Trials for Alopecia Areata Patients
Janus Kinase (JAK) Inhibitor
Baricitinib for Pediatric Hair Loss
This trial is testing baricitinib, a medication that may help treat severe hair loss. It targets children aged 6 to less than 18 years who have significant hair loss. The medication works by reducing the immune system's activity that causes hair loss.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alopecia Areata
This trial is testing baricitinib to see if it is safe and effective for adults with severe hair loss due to alopecia areata. The drug works by calming the immune system to prevent it from attacking hair follicles. Baricitinib was approved by the FDA for treating severe alopecia areata.
Stem Cell Therapy
Stem Cell Educator Therapy for Alopecia Areata
This trial is testing a new treatment called Stem Cell Educator therapy for people with alopecia areata, a condition that causes hair loss. The treatment uses the patient's own immune cells exposed to stem cells to help reset the immune system. It targets patients who haven't had success with other treatments. Stem Cell Educator therapy involves circulating a patient's blood through a system that allows immune cells to interact with stem cells, aiming to reset the immune system.
Trials for Male Pattern Baldness Patients
Neurotoxin
Botulinum Toxin for Androgenic Alopecia
This trial uses an injectable treatment known for reducing wrinkles to treat hereditary hair loss in adults. The injections are given in the scalp and may help improve hair growth by affecting muscles and blood flow.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Baricitinib for Pediatric Hair Loss
This trial is testing baricitinib, a medication that may help treat severe hair loss. It targets children aged 6 to less than 18 years who have significant hair loss. The medication works by reducing the immune system's activity that causes hair loss.
JAK Inhibitor
PF-06651600 for Alopecia Areata
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
Janus Kinase (JAK) Inhibitor
Baricitinib for Alopecia Areata
This trial is testing baricitinib to see if it is safe and effective for adults with severe hair loss due to alopecia areata. The drug works by calming the immune system to prevent it from attacking hair follicles. Baricitinib was approved by the FDA for treating severe alopecia areata.
JAK Inhibitor
CTP-543 for Alopecia Areata
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Janus Kinase (JAK) Inhibitor
Upadacitinib for Severe Alopecia Areata
This trial is testing upadacitinib, a medication that may help people with severe hair loss due to alopecia areata. The drug works by stopping the immune system from attacking hair roots. Adolescents and adults with severe alopecia areata are participating to see if this treatment is safe and effective.
Trials With No Placebo
Procedure
Mosaic Laser Treatment for Skin and Hair Conditions
This trial is testing a laser treatment called the Mosaic Ultra 1550nm system. It aims to help people with skin problems like wrinkles, scars, and acne. The laser works by boosting the skin's natural healing process to make it look smoother and younger. The 1550 nm laser device has been previously studied for its safety and effectiveness in improving wrinkles, pigmentation, and skin texture.
Behavioural Intervention
Cold Cap Therapy for Chemotherapy-Induced Hair Loss in Children
This trial will test if the Paxman scalp cooling device is safe and effective in preventing hair loss in pediatric patients receiving chemotherapy for non-cancerous conditions or solid tumors.
View More Related Trials
Frequently Asked Questions
Introduction to alopecia
What are the top hospitals conducting alopecia research?
When it comes to advancing research and treatment options for alopecia, several top hospitals are making remarkable contributions. In the vibrant city of New york, the Icahn School of Medicine at Mount Sinai leads the charge with six active trials focused on alopecia, building upon their history of 15 previous studies in this field since their first recorded trial in 2015. Meanwhile, ForCare Clinical Research in Tampa, Florida is also playing a significant role by currently conducting five alopecia trials. Since initiating their inaugural trial in 2018, they have already completed eight studies dedicated to understanding and treating this condition.
In Indianapolis, the Dawes Fretzin Clinical Research Group has been actively involved in furthering our knowledge about alopecia through four current clinical trials. With a total of ten completed studies under their belt since starting their first trial in 2016, this institution continues to contribute valuable insights into potential therapies for those affected by alopecia.
Moving further west towards Portland, NW Dermatology & Research Center LLC is focusing its efforts on four ongoing clinical trials for alopecia. Despite having a more recent start with their initial recorded trial taking place in 2015; they're steadily expanding our understanding and exploring various treatment possibilities for individuals living with this condition.
Lastly but certainly not least important is Dermatology Specialists of Charlotte situated within North carolina's charismatic city - Charlotte - where three active clinical trials are aimed at addressing the challenges faced by individuals with alopecia. While theirs can be seen as relatively recent endeavors marked only from commencement during year two thousand nineteen- that timeframe still accounts witnessing great strides made towards finding novel solutions promoting healthy hair growth proudly placing them amongst pioneers endeavoring better lives despite loss suffered due Alopecic conditions across regions nationwide
These specialized hospitals demonstrate unwavering commitment and dedication toward unraveling mysteries surrounding alopecia while striving tirelessly to find effective treatments and improve quality of life for those affected by this condition worldwide
Which are the best cities for alopecia clinical trials?
When it comes to alopecia clinical trials, several cities stand out as prominent research hubs. New york, San Antonio, and Portland all have 13 active trials each, focusing on various treatments such as Dupilumab, CTP-543, Baricitinib, and more. Minneapolis follows closely behind with 12 ongoing studies involving PF-06651600 and other interventions. Lastly, New Haven offers 10 active trials investigating treatments like Baricitinib and PF-06651600. These cities provide individuals dealing with alopecia an opportunity to participate in cutting-edge clinical research that may lead to advancements in treatment options for this condition.
Which are the top treatments for alopecia being explored in clinical trials?
Exciting developments are underway in the field of alopecia research, with several cutting-edge treatments currently being explored in clinical trials. Leading the charge is PF-06651600, a promising drug that has caught the attention of researchers worldwide. With three active trials and four all-time alopecia trials since its introduction in 2016, it shows great potential for addressing this challenging condition. Additionally, baricitinib and dupilumab have also emerged as strong contenders, each with two active and three all-time alopecia trials to their names. These innovative treatments may hold the key to unlocking new possibilities for individuals affected by alopecia, offering hope where there was once only frustration.
What are the most recent clinical trials for alopecia?
Exciting advancements are being made in the field of alopecia, with recent clinical trials offering promising possibilities for treatment. Among these trials is ADX-914, an experimental drug currently in Phase 2 testing, which could hold potential for individuals suffering from alopecia. Another trial that has shown promise is farudodstat, also in Phase 2, as well as dupilumab and oral minoxidil both at the same stage of development. Additionally, a topical solution called TDM-105795 is undergoing Phase 2 testing and may provide new options for those affected by alopecia. With these innovative studies underway, there is hope on the horizon for finding effective solutions to combat this condition.
What alopecia clinical trials were recently completed?
Recent clinical trials investigating potential treatments for alopecia have yielded promising results, offering hope to individuals affected by this condition. In April 2022, LEO Pharma completed a trial evaluating the efficacy of Delgocitinib cream. Similarly, in February 2022, Suzhou Kintor Pharmaceutical Inc. wrapped up a trial testing the GT20029 Gel treatment. Additionally, Technoderma Medicines Inc.'s TDM-105795 therapy underwent two separate trials that were completed in February 2022 and April 2021 respectively. Concert Pharmaceuticals' CTP-543 also demonstrated progress through its completion of a trial in February 2021. Although slightly further back on the timeline, Pfizer concluded their Etrasimod trial in July 2020 and the University of Arizona wrapped up their Keratinocyte growth factor study in April of that same year — both representing noteworthy contributions to alopecia research endeavors.